close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Shots of Intestinal Hormone Aid Weight Loss

Injections of the hormone oxyntomodulin may help overweight and obese people to lose weight, according to a 29 August report by MedPage Today.

Oxyntomodulin is a naturally occurring hormone released by the small intestine. Results of this recent study were published in the August issue of Diabetes

Background

Oxyntomodulin is a peptide hormone produced by the proglucagon gene. It is released from the small intestine into the bloodstream when a person ingests food and travels to the brain, where previous studies suggest it acts to enhance satiety and reduce appetite.

By administering oxyntomodulin before meals, it is possible to “fool the brain that you have already eaten,” says the research team, led by Katie Wynne, MRCP, a clinical research fellow at Hammersmith Hospital in London, according to MedPage Today.

“When we give oxyntomodulin artificially before meals we are using the natural system by which the body controls appetite. We would not expect either side effects or escape from its action because you have had it every day since you were born.”

Clinical Trial Results

The study included 14 study participants who self-injected oxyntomodulin three times daily before meals while maintaining a normal diet and exercise levels. After four weeks, they had reduced overall body weight by 2% (2.3 ± 0.4 kg versus 0.5 ± 0.5 kg lost by another 12 subjects receiving placebo saline injections).

However, within two weeks of stopping oxyntomodulin injections, participants regained the lost weight.

“These preliminary data suggest that the administration of oxyntomodulin could be an effective treatment for obesity," Dr. Wynne and colleagues reported in the Diabetes study.

Study participants receiving oxyntomodulin ate less than usual, despite being asked to maintain normal eating habits, because of oxyntomodulin’s satiety-inducing effect. Researchers measured energy intake at mealtime on days 1, 2 and 29 (for meals with known energy content). Intake by participants receiving oxyntomodulin was significantly lower on days 2 and 29, compared with day 1, while the placebo group’s energy intake remained stable.

Adipose hormone levels (leptin and adiponectin) significantly changed among subjects receiving oxyntomodulin, a characteristic consistent with adipose-tissue loss.

Sources:

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...